Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases.

Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, de Wilde RF, Brosens LA, Rezaee N, Javed A, Gobbo S, Regi P, Salvia R, Bassi C, He J, Weiss MJ, Cameron JL, Offerhaus GJA, Hruban RH, Lawlor RT, Scarpa A, Heaphy CM, Wood LD, Wolfgang CL.

Ann Surg. 2018 Oct 17. doi: 10.1097/SLA.0000000000003022. [Epub ahead of print]

PMID:
30339629
2.

Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function.

Rajeshkumar NV, Dutta P, Yabuuchi S, de Wilde RF, Martinez GV, Le A, Kamphorst JJ, Rabinowitz JD, Jain SK, Hidalgo M, Dang CV, Gillies RJ, Maitra A.

Cancer Res. 2015 Aug 15;75(16):3355-64. doi: 10.1158/0008-5472.CAN-15-0108. Epub 2015 Jun 25.

3.

Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis.

Dal Molin M, Zhang M, de Wilde RF, Ottenhof NA, Rezaee N, Wolfgang CL, Blackford A, Vogelstein B, Kinzler KW, Papadopoulos N, Hruban RH, Maitra A, Wood LD.

Clin Cancer Res. 2015 Apr 15;21(8):1944-50. doi: 10.1158/1078-0432.CCR-14-2600. Epub 2015 Jan 26.

4.

Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma.

Chen R, Dawson DW, Pan S, Ottenhof NA, de Wilde RF, Wolfgang CL, May DH, Crispin DA, Lai LA, Lay AR, Waghray M, Wang S, McIntosh MW, Simeone DM, Maitra A, Brentnall TA.

Lab Invest. 2015 Jan;95(1):43-55. doi: 10.1038/labinvest.2014.128. Epub 2014 Oct 27.

5.

Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.

Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV.

Cancer Lett. 2013 Jul 10;335(1):41-51. doi: 10.1016/j.canlet.2013.01.054. Epub 2013 Feb 10.

6.

Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas.

Nguyen DN, Heaphy CM, de Wilde RF, Orr BA, Odia Y, Eberhart CG, Meeker AK, Rodriguez FJ.

Brain Pathol. 2013 May;23(3):237-43. doi: 10.1111/j.1750-3639.2012.00630.x. Epub 2012 Sep 24.

7.

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H.

Oncotarget. 2012 Jul;3(7):709-22.

8.

Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populations.

Chun YS, Bisht S, Chenna V, Pramanik D, Yoshida T, Hong SM, de Wilde RF, Zhang Z, Huso DL, Zhao M, Rudek MA, Stearns V, Maitra A, Sukumar S.

Carcinogenesis. 2012 Nov;33(11):2242-9. doi: 10.1093/carcin/bgs248. Epub 2012 Jul 25.

9.

Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma.

Chen R, Pan S, Ottenhof NA, de Wilde RF, Wolfgang CL, Lane Z, Post J, Bronner MP, Willmann JK, Maitra A, Brentnall TA.

Cancer Biol Ther. 2012 Aug;13(10):899-907. doi: 10.4161/cbt.20842. Epub 2012 Aug 1.

10.

The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.

Mizuma M, Rasheed ZA, Yabuuchi S, Omura N, Campbell NR, de Wilde RF, De Oliveira E, Zhang Q, Puig O, Matsui W, Hidalgo M, Maitra A, Rajeshkumar NV.

Mol Cancer Ther. 2012 Sep;11(9):1999-2009. doi: 10.1158/1535-7163.MCT-12-0017. Epub 2012 Jul 2.

11.

Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.

de Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH, Wolfgang CL, Ellison TA, Schulick RD, Molenaar IQ, Valk GD, Vriens MR, Borel Rinkes IH, Offerhaus GJ, Hruban RH, Matsukuma KE.

Mod Pathol. 2012 Jul;25(7):1033-9. doi: 10.1038/modpathol.2012.53. Epub 2012 May 11.

12.

Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.

de Wilde RF, Edil BH, Hruban RH, Maitra A.

Nat Rev Gastroenterol Hepatol. 2012 Feb 7;9(4):199-208. doi: 10.1038/nrgastro.2012.9. Review.

13.

Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, Demarzo AM, Shi C, Sharma R, Laheru D, Edil BH, Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue CA.

Am J Surg Pathol. 2012 Feb;36(2):173-84. doi: 10.1097/PAS.0b013e3182417d36.

14.

Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality.

de Wilde RF, Besselink MG, van der Tweel I, de Hingh IH, van Eijck CH, Dejong CH, Porte RJ, Gouma DJ, Busch OR, Molenaar IQ; Dutch Pancreatic Cancer Group.

Br J Surg. 2012 Mar;99(3):404-10. doi: 10.1002/bjs.8664. Epub 2012 Jan 11.

PMID:
22237731
15.

Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways.

Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI, Schulick RD, Edil BH, Choti MA, Adsay V, Klimstra DS, Offerhaus GJ, Klein AP, Kopelovich L, Carter H, Karchin R, Allen PJ, Schmidt CM, Naito Y, Diaz LA Jr, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B.

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21188-93. doi: 10.1073/pnas.1118046108. Epub 2011 Dec 8.

16.

Molecular determinants of retinoic acid sensitivity in pancreatic cancer.

Gupta S, Pramanik D, Mukherjee R, Campbell NR, Elumalai S, de Wilde RF, Hong SM, Goggins MG, De Jesus-Acosta A, Laheru D, Maitra A.

Clin Cancer Res. 2012 Jan 1;18(1):280-9. doi: 10.1158/1078-0432.CCR-11-2165. Epub 2011 Oct 18.

17.

Pancreatic ductal adenocarcinoma in hereditary diffuse gastric cancer. A case report.

Ottenhof NA, de Wilde RF, Morsink FH, de Leng WW, Ausems MG, Morreau H, van Hillegersberg R, Offerhaus GJ, Milne AN.

Hum Pathol. 2012 Mar;43(3):457-61. doi: 10.1016/j.humpath.2011.06.008. Epub 2011 Oct 10.

18.

Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas.

Dal Molin M, Hong SM, Hebbar S, Sharma R, Scrimieri F, de Wilde RF, Mayo SC, Goggins M, Wolfgang CL, Schulick RD, Lin MT, Eshleman JR, Hruban RH, Maitra A, Matthaei H.

Hum Pathol. 2012 Apr;43(4):585-91. doi: 10.1016/j.humpath.2011.06.009. Epub 2011 Sep 21.

19.

Altered telomeres in tumors with ATRX and DAXX mutations.

Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK.

Science. 2011 Jul 22;333(6041):425. doi: 10.1126/science.1207313. Epub 2011 Jun 30.

20.

Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma.

de Wilde RF, Ottenhof NA, Jansen M, Morsink FH, de Leng WW, Offerhaus GJ, Brosens LA.

Mod Pathol. 2011 Sep;24(9):1229-36. doi: 10.1038/modpathol.2011.83. Epub 2011 May 13.

21.

Molecular characteristics of pancreatic ductal adenocarcinoma.

Ottenhof NA, de Wilde RF, Maitra A, Hruban RH, Offerhaus GJ.

Patholog Res Int. 2011 Mar 27;2011:620601. doi: 10.4061/2011/620601.

22.

Experimental animal models in scoliosis research: a review of the literature.

Janssen MM, de Wilde RF, Kouwenhoven JW, Castelein RM.

Spine J. 2011 Apr;11(4):347-58. doi: 10.1016/j.spinee.2011.03.010. Review.

23.

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N.

Science. 2011 Mar 4;331(6021):1199-203. doi: 10.1126/science.1200609. Epub 2011 Jan 20.

24.

mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.

Kl├╝mpen HJ, Queiroz KC, Spek CA, van Noesel CJ, Brink HC, de Leng WW, de Wilde RF, Mathus-Vliegen EM, Offerhaus GJ, Alleman MA, Westermann AM, Richel DJ.

J Clin Oncol. 2011 Feb 20;29(6):e150-3. doi: 10.1200/JCO.2010.32.7825. Epub 2010 Dec 28. No abstract available.

25.

The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program.

Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A, Pan D.

Genes Dev. 2010 Nov 1;24(21):2383-8. doi: 10.1101/gad.1978810.

Supplemental Content

Loading ...
Support Center